Table 4.
PRMT5 expression in NET
| Cytoplasmic high PRMT5, n (%) | P | Nuclear high PRMT5, n (%) | P | N a | ||
|---|---|---|---|---|---|---|
| Age |
≤60 years (n = 59) |
8 (6.3) |
0.43 |
12 (9.4) |
0.61 |
128 |
| >60 years (n = 69) |
12 (9.4) |
19 (14.8) |
||||
| Gender |
Female (n = 62) |
7 (5.4) |
0.33 |
18 (14.0) |
0.16 |
129 |
| Male (n = 67) |
14 (10.9) |
13 (10.1) |
||||
| Size |
≤3 cm (n = 69) |
9 (8.3) |
0.71 |
19 (17.6) |
0.76 |
108 |
| >3 cm (n = 39) |
7 (6.5) |
11 (10.2) |
||||
| Stage |
I (n = 69) |
12 (12.0) |
0.48 |
17 (17.0) |
0.42 |
100 |
| II-IV (n = 31) |
7 (7.0) |
10 (10.0) |
||||
| Histology |
Carcinoid (n = 63) |
6 (4.5) |
0.04 |
22 (16.5) |
0.02 |
133 |
| HG-NET (n = 70) |
16 (12.0) |
10 (7.5) |
||||
| Survival | Yes (n = 46) |
8 (8.0) |
0.923 | 16 (16.0) |
0.02 | 100 |
| No (n = 54) | 9 (9.0) | 8 (8.0) |
Abbreviations: Neg negative, N number of cases, HG-NET high grade neuroendocrine tumors.
a Reflects total number of cases with available annotations.